MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze MOBI →
    • FindStock Picks / Stock Screener
    • Value · MOBIIntrinsic Value Calculator
    • Invest · MOBIInvestment Case
    • Hold · MOBI5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
MOBI

MOBI

Mobia Medical, Inc. Common Stock

$8.09
-0.22
 (-2.65%)
Exchange:  NASDAQ
Market Cap:  269.325M
Shares Outstanding:  23.05M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – SpecialtiesView industry performance
   
CEO:  Richard Foust
Full Time Employees:  167
Address: 
2802 Flintrock Trace
Austin
TX
78738
US
Website:  https://www.mobia.com
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
MOMOBI logoMOBIMobia Medical, Inc. Common Stock269.3M——-19.2%
ANANIK logoANIKAnika Therapeutics, Inc.267.4M—19.0-3.2%
LALAB logoLABStandard BioTools Inc.246.9M——-8.3%
SISI logoSIShoulder Innovations, Inc.376.6M——-25.3%
NYNYXH logoNYXHNyxoah S.A.113.0M——-59.9%
APAPYX logoAPYXApyx Medical Corporation107.4M——-6.8%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year2025
Revenue32,040.978
Gross Profit25,975.023
EBITDA-45,373.713
Operating Income-46,367.901
Net Income-46,498.188

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year2025
Total Assets48,148.699
Total Liabilities198,922.286
Total Stockholders Equity-150,773.587
Total Debt8,435.336
Cash and Cash Equivalents33,587.308

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year2025
Operating Cash Flow-45,694.990
Capital Expenditure-364.411
Free Cash Flow-46,059.401
Net Income-46,498.188
Net Change in Cash18,966.988

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)236,685.100Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)241,979.734Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)238,500Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-12,610.326Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-12,191.274Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-12,334.876Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-14,797.059Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)-14,378.007Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)-14,521.609Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)486,265.738Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)497,143.479Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)489,994.421Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)-0.630Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)-0.620Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-0.640Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
11.22
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-5.26
?Enterprise Value
 (TTM)
: 
118.276M  ?EV/FCF
 (TTM)
: 
-3.38
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
79.74%  ?ROIC
 (TTM)
: 
-19.24%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.05
?P/B
 (TTM)
: 
0.95  ?Current Ratio
 (TTM)
: 
13.28

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates MOBI intrinsic value between $62.06 – $62.06 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate MOBI Intrinsic Value

Common questions about MOBI valuation

Is Mobia Medical, Inc. Common Stock (MOBI) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Mobia Medical, Inc. Common Stock (MOBI) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is MOBI a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MOBI trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is MOBI’s P/E ratio?

You can see MOBI’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for MOBI?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is MOBI a good long-term investment?

Whether MOBI fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Mobia Medical, Inc. Common Stock

  • Mobia Medical, Inc. Common Stock intrinsic value calculatorEstimate what the business is worth
  • Mobia Medical, Inc. Common Stock 5-year outlookWhat has to go right, and what could go wrong
MOBI

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-2.65
MarketSnap

Trading Metrics:

Open: 8.31   Previous Close: 8.31
Day Low: 8.04   Day High: 8.33
Year Low: 8.04   Year High: 15.29
Price Avg 50: 10.38   Price Avg 200: 11.56
Volume: 80625   Average Volume: 178228

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Mobia Medical, Inc. (NASDAQ:MOBI) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
05-10-2026 04:14
Mobia Medical, Inc. (NASDAQ:MOBI) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy
14-07-2026 16:18
Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze MOBI →
    • FindStock Picks / Stock Screener
    • Value · MOBIIntrinsic Value Calculator
    • Invest · MOBIInvestment Case
    • Hold · MOBI5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read